BIOA BioAge Labs, Inc: Rasio rega marang prakiraan pendapatan

The lack of profitability and reliance on venture capital create risks, yet the forward P/S of BioAge Labs, Inc. (BIOA) illustrates market optimism. The value 30.00 shows the level of this metric. Confidence is fueled by the success of azelaprag in combating obesity and strategic alliances to study aging processes, which opens a path for BioAge Labs, Inc. (BIOA) toward large-scale partnerships with pharma behemoths.

BioAge - Rasio kapitalisasi marang dodolan sing dikarepake BIOA (periode 08.05.2025 - 13.11.2026)

Ringkesan rincian data analitis BioAge Labs, Inc (BIOA)

- rega pasar lan target rega analis:

Bagan rega BioAge|BIOA - Rata-rata rega prakiraan

- data kapitalisasi saham perusahaan:

Nilai pasar BioAge Labs, Inc|BIOA - Nilai Total Perusahaan

- indikator nilai buku ekuitas:

Nilai Buku saben Saham BioAge Labs, Inc.|BIOA - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku bioagelabs.com|BIOA - Gunggung Aset Perusahaan

- rincian struktur utang lan likuiditas bisnis:

- rincian asil keuangan lan kelipatan valuasi:

BIOA - Bathi resik|Proyeksi bathi mangsa ngarep BioAge Labs, Inc.|BIOA - Rasio kapitalisasi marang bathi resik|Pangali Forward P/E BioAge Labs Inc.|BIOA - Rega marang bathi kanthi panyesuaian wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan BioAge Labs, Inc|BIOA - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan BioAge Labs, Inc.|BIOA - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi EPS kuartalan bioagelabs.com|BIOA - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep BioAge Labs, Inc.

- indikator volume dodolan lan pendapatan:

BIOA - Pendapatan perusahaan|Prakiraan pendapatan perusahaan BioAge|BIOA - Koefisien rega marang pendapatan|Multiplikator forward rega marang pendapatan BioAge Labs, Inc

Ringkesan analitik perusahaan:BioAge BIOA

To minimize investment risks, it is critical to track the dynamics of market expectations regarding the future revenue of BioAge Labs, Inc. (BIOA) within the longevity medicine sector. An analysis of the projected P/S multiple allows for an assessment of the market's willingness to pay a premium for AI-driven metabolic analysis technologies by comparing current capitalization with projected earnings from the development of innovative drugs.

Analisis perusahaan pesaing

Rasio rega marang prakiraan pendapatan Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan NewAmsterdam Pharma N.V. (NAMS)|Multiplikator forward rega marang pendapatan Soleno Therapeutics Corp SLNO|Multiplikator Forward P/S FOLD (Amicus Therapeutics)|89bio.com - Rasio rega marang prakiraan pendapatan|Agios Pharmaceuticals, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Structure Therapeutics Inc GPCR|MiMedx Group (MDXG) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Rezolute Bio (RZLT)|LXRX (Lexicon Pharmaceuticals) - Multiplikator Forward P/S|Multiplikator Forward P/S mbxbio.com|Multiplikator Forward P/S ALT|Aardvark Therapeutics Inc. (AARD) - Prakiraan rega marang pendapatan|Multiplikator Forward P/S SGMT (Sagimet)|Biomea Fusion Corp (BMEA) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|QNCX: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan GUTS (fractyl.com)|vtvtherapeutics.com (VTVT) - Rasio rega marang prakiraan pendapatan|ATPC (Agape ATP) - Rasio rega marang prakiraan pendapatan|PLUR (Pluristem Therapeutics) - Multiplikator Forward P/S|Multiplikator Forward P/S Synlogic Corp|Multiplikator Forward P/S LPCN|Rasio rega marang prakiraan pendapatan MTNB (matinasbiopharma.com)|Rasio rega marang prakiraan pendapatan Spruce Biosciences, Inc. SPRB|Rasio kapitalisasi marang dodolan sing dikarepake Galecto Inc (GLTO)|CTCX: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan LUMO (Lumos Therapeutics)|ONVO: Multiplikator Forward P/S|RDUS - Rasio kapitalisasi marang dodolan sing dikarepake